AGENDA AT A GLANCE

DAY 1
DAY 2

Unlocking Commercial Success & Global Supply in DACH’s Cell & Gene Therapy

Quality Assurance in CGT
Decentralised Production for Next-Gen Cell & Gene Therapies
Novel Purification & Intensification Strategies
Overcoming Bottlenecks in Viral Vector Manufacturing
Manufacturing Innovations for Allogeneic and In Vivo Therapies
Industry Roundtables: What's Next for Bioprocessing in CGT?
Smart Factories: The Role of Digitalisation & AI
Key Takeaways
Supply Chain & Logistics
Drink Reception
End of Conference
VIEW DAY 1
VIEW DAY 2

Day 1

11 February 2026

GO TO DAY 2

8:30

Registration & Coffee

Unlocking Commercial Success in DACH’s Cell & Gene Therapy

9:00

Opening Keynote: Pathways for CGT in Germany, Austria & Switzerland

Alessandro Linciano | Site MSAT Head, Cell & Gene Therapy, Novartis, Switzerland

9:25

A Global Vision for Cell and Gene Therapies

Karin Abitorabi | Head Process Development and Innovation, Minaris Advanced Therapies, Germany

9:50

Accelerating Innovation through Translational Incubators

Dr. Marion Hitchcock | Managing Director Gene & Cell Therapies Incubator Berlin, Bayer, Germany

10:15

TBC

Cristina Castro González de Vega | Head, Cell & Gene Value Chain Product Management, Roche, Switzerland

10:40

Networking Break

Decentralised Production for Next-Gen Cell & Gene Therapies

11:15

Decentralising Cell Therapy

Dr. Jan Spanholtz | CSO, Glycostem, Germany

11:40

Real-Time Monitoring & Control Systems in Automated CGT Workflows

12:20

Lunch Break

Overcoming Bottlenecks in Viral Vector Manufacturing

13:20

Innovative Adsorptive Separation Strategies for Viral Gene Therapy Vectors

Loredana Siani | Senior VP of Technical and CMC development, Nouscom, Italy

13:45

Reserved for Solution Provider

14:10

Panel Discussions: How to Reduce Manufacturing Costs in CGT

Moderator

Dr. Henrieta Fraser | Head Of External Operations, Cell & Gene Therapy Catapult, UK

Panelists

Alois Jungbauer | Professor, BOKU University, Austria
Roman Mijnhart | Executive Director, Head of Quality EU, Ultragenyx, Netherlands
Loredana Siani | Senior VP of Technical and CMC development, Nouscom, Italy
Volker Huppert | Chief Development Officer, Glycostem, Germany

14:45

Networking Break

15:30

Roundtable Discussions

  • Best Practices for Scaling Autologous Therapies: What's Working Today?
John Bridgeman | CSO, Immunokey, UK
  • Ensuring GMP Compliance in Closed System Environments
Volker Huppert | Chief Development Officer, Glycostem, Germany
  • Commercialisation CART Ts
Arindam Mitra | Director CMC, Leucid Bio, UK
  • Automation in Allogeniec Cell Therapy Manufacturing
Dr. Jan Spanholtz | CSO, Glycostem, Germany
  • Standardisation of MSC Clinical Trials for Commercial Succes
Loredana Siani | Senior VP of Technical and CMC development, Nouscom, Italy
  • Strategic Approaches for Successful Cell & Gene Therapy Launches
Mayra Battilani Becegato | Former EMEA Commercial Strategy Director Gene Therapy - Rare Diseases, J&J Innovative Medicine, Belgium

17:00

Key Takeaways

17:15

END OF DAY 1

Want to Speak at This Event?

Join the roster of esteemed colleagues to discuss what you or your company are bringing to the biopharmaceutical industry.

Apply to Speak

Day 2

12 February 2026

GO TO DAY 1

8:30

Registration & Coffee

Quality Assurance in CGT

9:00

CGT Inspections challenges from a quality perspective

Brian O Connor | VP Global Quality, Orchard Therapeutics, UK

9:25

Redefining Quality Assurance for Autologous and Allogeneic CGT: From Batch Release to Real-Time Oversight

Roman Mijnhart | Executive Director, Head of Quality EU, Ultragenyx, Netherlands

9:50

Reserved for Solution Provider

10:20

Networking Break

Novel Purification & Intensification Strategies

10:45

Next-Gen Purification Platforms for Viral Vectors: Enhancing Yield and Throughput at Scale

Alois Jungbauer, Professor, BOKU University, Austria

11:10

Reserved for Solution Provider

11:35

Intensification by Design: Leveraging Continuous Processing & High-Density Cultures in CGT Manufacturing

Thomas Villiger, Professor of Bioprocess Technology, University of Applied Sciences and Arts Northwestern Switzerland FHNW, Switzerland

12:00

Lunch Break

Manufacturing Innovations for Allogeneic and In Vivo Therapies

13:00

Developing a Next Generation CAR T-cell Therapy

Dr. John Bridgeman | CSO, Immunokey, United Kingdom

13:25

Ensuring Genomic Integrity in Therapeutic Genome Editing: Mitigating Off-Target Risks in CGT Development

Dr. Toni Cathomen | Chair & Professor of Cell and Gene Therapy, Director, University Medical Center Freiburg, Germany

13:50

TBC

Arindam Mitra | Director CMC, Leucid Bio, United Kingdom

14:15

Networking Break

Smart Factories: The Role of Digitalisation & AI

14:30

Panel Discussion - Perspectives/Value/Expectations of AI on CGT Manufacturing

Moderator

Pilar Redondo | Site Head , Takeda Spain

Panelists

Gabriella Cotugno | Head of Vector Construction and Development, Nouscom, Italy
Dr. Jan Spanholtz | CSO, Glycostem, Germany
Arindam Mitra | CMC Director, Leucid Bio, UK

15:10

Application of Digital Twins in Biologics Development and Manufacturing

Thomas Sauer | Head of Microbial Platform, Global CMC Development, Sanofi, Germany

Supply Chain & Logistics

15:35

Transport Validation & It's Impact on Site Selection & Global Logistics

Marcel van Houten | Director Global Supply Chain, Orchard Therapeutics, Switzerland

16:00

Building Resilient Supply Networks for Biologics Manufacturing

16:30

Chairman’s Closing Rearks

16:30

END OF CONFERENCE

Get Your Ticket
View the 2025 Post-Event Report